Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Laboratories Ltd.

www.drreddys.com

Latest From Dr. Reddy's Laboratories Ltd.

Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Regulation United States

AZ's Brilinta Patents 'Vulnerable' To Challenge In India

An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.

India Intellectual Property

Cutbacks Rise As Indian Pharma Tightens Control On Costs

Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.

India Commercial

AstraZeneca Seeks To Block Dr Reddy’s US Brilinta Rival

AstraZeneca has petitioned a US court to stop India’s Dr Reddy’s from launching a generic version of its blood clot-fighting drug Brilinta, accusing the Indian drugmaker of patent infringement.

Generic Drugs Legal Issues
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register